Your browser doesn't support javascript.
loading
Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas.
Song, Y; Yoon, D H; Yang, H; Cao, J; Ji, D; Koh, Y; Jing, H; Eom, H; Kwak, J; Lee, W; Lee, J; Shin, H; Jin, J; Wang, M; Yang, Z; Kim, W S; Zhu, J.
Afiliación
  • Song Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China.
  • Yoon DH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Yang H; Department of Lymphoma, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou.
  • Cao J; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Ji D; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Koh Y; Department of Internal Medicine, Division of Hematology and Medical Oncology, Seoul National University Hospital, Seoul, South Korea.
  • Jing H; Department of Hematology and Lymphoma Research Center, Peking University Third Hospital, Beijing, China.
  • Eom H; Hematology-Oncology Clinic, National Cancer Center, Goyang.
  • Kwak J; Department of Internal Medicine, Chonbuk National University Medical School, Jeonju.
  • Lee W; Department of Hematology-Oncology, Inje University College of Medicine, Busan Paik Hospital, Busan.
  • Lee J; Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam.
  • Shin H; Division of Hematology-Oncology, Department of Internal Medicine, Medical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, South Korea.
  • Jin J; Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou.
  • Wang M; Dizal Pharmaceutical, Jiangsu, China.
  • Yang Z; Dizal Pharmaceutical, Jiangsu, China.
  • Kim WS; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Electronic address: wskimsmc@skku.edu.
  • Zhu J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China. Electronic address: zhujun@csco.org.cn.
Ann Oncol ; 34(11): 1055-1063, 2023 11.
Article en En | MEDLINE | ID: mdl-37673210
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma de Células T Periférico Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma de Células T Periférico Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: China